DTIL Stock Analysis: Buy, Sell, or Hold?
DTIL - Precision BioSciences, Inc. Common Stock
$8.18
0.30 (3.81%)
▲
5d:
+21.19%
30d:
+29.43%
90d:
+43.76%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When DTIL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: DTIL is 13.8% above its trading range ($7.19). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: DTIL is 13.8% above its trading range ($7.19). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: DTIL is currently trading at $8.18, which is considered extended relative to its 30-day fair value range of $6.36 to $7.19.
Technical Outlook: Technically, DTIL is in a strong uptrend. The price is approaching resistance at $8.22. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: DTIL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.60 (+261.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DTIL is in a strong uptrend. The price is approaching resistance at $8.22. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: DTIL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.60 (+261.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.36 -
$7.19
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+13.8% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BULLISH: Trading 261.9% below Wall St target ($29.60)
Trading Range Analysis
30-Day Trading Range
$6.36 -
$7.19
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.00
Resistance Level
$8.22
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.32
Wall Street Target
$29.60
(+261.9%)
Revenue Growth (YoY)
37272.4%
Profit Margin
-96.7%
Share & Embed Analysis
Last updated: July 02, 2026 10:40 PM ET
Data refreshes hourly during market hours. Next update: 11:40 PM
Data refreshes hourly during market hours. Next update: 11:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DTIL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
J. Jefferson Smith
SELL
4925 shares
2026-02-18
John Alexander Kelly
SELL
8149 shares
2026-02-18
Michael Amoroso
SELL
20559 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
